

June 29, 2007



## Oncolytics Biotech Inc. Announces Issuance of 6th Canadian Patent

CALGARY, June 29 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ("Oncolytics") announced today that it has been granted Canadian Patent 2,437,468 entitled "Sensitization of Chemotherapeutic Agent Resistant Neoplastic Cells with Reovirus." The claims describe using a combination of reovirus and chemotherapy to treat cancer patients, and particularly those who are resistant to or may develop resistance to chemotherapeutic treatments. The patent also includes composition of matter claims.

"Securing this patent adds to our growing patent portfolio in the area of combination therapy with REOLYSIN(R)," said Dr. Brad Thompson, President and Chief Executive Officer of Oncolytics.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics please visit [www.oncolyticsbiotech.com](http://www.oncolyticsbiotech.com)

This news release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including among others, the Company's belief as to the importance of the issuance of this patent, the safety and efficacy of the reovirus, the Company's expectations as to the potential applications of the patented technology and other statements relating to anticipated developments in the Company's business and technologies, involve known and unknown risks and uncertainties that could cause the Company's actual results to differ materially from those in the forward looking statements. Such risks and uncertainties include, among others, the efficacy of REOLYSIN(R) as a cancer treatment, the success and timely completion of clinical studies and trials, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements.

SOURCE Oncolytics Biotech Inc.